Non-Hodgkin Lymphoma
News
New data added to obinutuzumab label
Credit: Bill Branson The US Food and Drug Administration (FDA) has approved a supplemental biologics license application for obinutuzumab (Gazyva...
Conference Coverage
Approach can cure even high-risk FL, study suggests
The study showed that many patients transplanted in complete remission (CR) did not relapse and could be considered cured. Patients transplanted...
Conference Coverage
Antibody shows activity in relapsed/refractory NHL
“It is encouraging to see results in an NHL study that selects a different target than CD20,” said Kristie Blum, MD, of The Ohio State University...
News
Drug gets orphan designation for MM & CLL/SLL
The European Medicines Agency (EMA) has granted orphan drug designation for selinexor (KPT-330) to treat multiple myeloma (MM) and chronic...
News
EZH2 inhibitor is active in NHL with wild-type EZH2
BARCELONA—A small molecule inhibitor of EZH2 has shown “encouraging” activity in patients with advanced non-Hodgkin lymphoma (NHL), according to...
News
Chemo and CAR T cells prompt responses in NHL
However, patients also experienced significant acute toxicities, including fever, low blood pressure, focal neurological deficits, and delirium....
News
Combo appears safe and active in CLL, NHL
Credit: Linda Bartlett KOHALA COAST, HAWAII—Early results of a small, phase 1 study suggest a novel combination treatment is active and generally...
News
Drug approved to treat NHL in Israel
The Israeli Ministry of Health has granted approval for the antineoplastic agent pixantrone (Pixuvri). The drug is now approved as monotherapy...
Conference Coverage
Study validates drug’s efficacy in CLL/SLL
Ibrutinib conferred these benefits irrespective of baseline clinical characteristics or molecular features, including 17p deletion. Atrial...
News
Ofatumumab falls short in CLL, DLBCL
Credit: Linda Bartlett The anti-CD20 antibody ofatumumab (Arzerra) has failed to meet the primary endpoint in two phase 3 trials, according to...
Conference Coverage
Approach can reduce drug-induced TLS
Photo courtesy of EHA MILAN—The BCL-2 inhibitor ABT-199 may be a feasible treatment option for patients with chronic lymphocyctic leukemia/small...